Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Silence Therapeutics bolsters board

Silence Therapeutics has hired Stuart Collinson as a non-executive director as Simon Sturge resigns to take up other business commitments
Silence Therapeutics bolsters board
Experienced Collinson, 55, has held senior management roles at GlaxoWellcome, now GlaxoSmithKline and Baxter International...

Silence Therapeutics (LON:SLN) has hired Stuart Collinson as a non-executive director as Simon Sturge resigns to take up other business commitments.

Experienced Collinson, 55, has held senior management roles at GlaxoWellcome, now GlaxoSmithKline and Baxter International and was chairman, chief executive and president of previously listed Aurora Biosciences, which was acquired by Vertex Pharmaceuticals (NASDAQ:VRTX) in 2001.

He has held various positions in public and private life science companies in the US and Europe and is a partner of Forward Ventures, a biopharmaceutical venture capital fund.

Ali Mortazavi, the chief executive of Silence Therapeutics, said: "We are very pleased to welcome Stuart to our board, who brings with him extensive experience in the sector with a business development and M&A track record across the US and Europe."

Shares were unchanged at 137.875p.

Giles_55af4ddca6481.jpg
Why Invest In Silence Therapeutics plc? Read More Here

Register here to be notified of future SLN Company articles
View full SLN profile

Silence Therapeutics plc Timeline

Newswire
September 27 2016

Related Articles

shutterstock_255595165.jpg
July 26 2016
Chief executive Cameron Reynolds told Proactive: "It's one thing to be a science project. It's another to have products and we are right on the cusp of that.”
newspaper with word cancer magnified
January 30 2017
The start of 2017 has seen some good trial results for its skin cancer treatment, as well as a collaboration deal that will accelerate the development of its lung cancer drug
shutterstock_327930536.jpg
December 02 2016
Life sciences firm ValiRx is poised for a busy year ahead as it progresses its lead drugs...

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.